3 Results
The construction of an efficient biocatalytic in vivo cascade
necessitates a balanced expression of the cascade genes to avoid side
product accumulation. Besides the well-characterized initiating Cyp[18, 21], CDH and CHMO have been employed for PCL
monomer synthesis from cyclohexane [16], but
nothing is known about respective reaction kinetics and possible
inhibitions by pathway intermediates as they have been observed before,
e.g., for Bayer-Villiger monooxygenases [22, 23].
Consequently, CDH and CHMO were characterized as the first step in this
study to support the rational engineering of a productive 3-step cascade
based on the optimized Cyp-containing whole-cell biocatalyst[18].